Cabazitaxel is a novel taxane antineoplastic agent, which stabilises the microtubule network by binding to tubulin, thereby preventing the breakdown required for cancer cell division.1
The open-label, randomised phase 3 TROPIC study (n=755) compared the efficacy and safety of cabazitaxel against mitoxantrone, both in combination with either prednisone or prednisolone, in patients with hormone-refractory metastatic prostate cancer who had previously received a docetaxel-containing regimen. The primary endpoint used was overall survival.2
The data were analysed on an intention to treat basis. At the cut-off for final analysis, median overall survival was longer in the cabazitaxel group (15.1 months) than in the mitoxantrone group (12.7 months; p<0.0001), indicating that cabazitaxel provides a 30% reduction in the risk of death compared with mitoxantrone.2
In addition, median progression-free survival was approximately doubled in patients treated with cabazitaxel (2.8 months) compared with those who received mitoxantrone (1.4 months; p<0.0001).2
There was no significant difference between treatment arms with regard to pain progression or pain response.2
- Jevtana Summary of Product Characteristics, March 2011.
- de Bono JS et al. Lancet 2010; 376: 1147–54.
Further Information: Sanofi–aventis